Danicopan: meta-analysis of COVID-19 studies

All studies Mortality Ventilation Hospitalization Serious outcomes Recovery RCTs RCT mortality All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−43%

Mortality (1)−43%

Ventilation (1)−17%

Hospitalization (1)−19%

RCTs (1)−43%

Late (1)−43%

00.511.5+

← Danicopan
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

Danicopan COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Beigel (DB RCT)−43%1.43 · 0.76–2.68death19/9814/103ACTIV-5 BET-C

Late treatment−43%1.43 · 0.76–2.6819/9814/10343% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.27

All studies−43%1.43 · 0.76–2.6819/9814/10343% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.2700.511.52+

Rotate screen for more detailsIncrease width for more details

← Danicopan
reduces riskDanicopan
increases risk →

c19early.org

October 2026

Danicopan COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Beigel (DB RCT)−43%1.43 · 0.76–2.6819/9814/103ACTIV-5 BET-C

Late treatment−43%1.43 · 0.76–2.6819/9814/10343% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.27

All studies−43%1.43 · 0.76–2.6819/9814/10343% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.2700.511.52+

Rotate screen for more detailsIncrease width for more details

← Danicopan
reduces riskDanicopan
increases risk →

c19early.org

October 2026

Danicopan COVID-19 mechanical ventilation results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Beigel (DB RCT)−17%1.17 · 0.61–2.2516/9114/93ACTIV-5 BET-C

Late treatment−17%1.17 · 0.61–2.2516/9114/9317% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.66

All studies−17%1.17 · 0.61–2.2516/9114/9317% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.6600.511.52+

Rotate screen for more detailsIncrease width for more details

← Danicopan
reduces riskDanicopan
increases risk →

c19early.org

October 2026

Danicopan COVID-19 hospitalization results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Beigel (DB RCT)−19%1.19 · 0.80–1.76hosp. time96 (n)99 (n)ACTIV-5 BET-C

Late treatment−19%1.19 · 0.80–1.7696 (n)99 (n)19% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.4

All studies−19%1.19 · 0.80–1.7696 (n)99 (n)19% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.400.511.52+

Rotate screen for more detailsIncrease width for more details

← Danicopan
reduces riskDanicopan
increases risk →

c19early.org

October 2026

Danicopan COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Beigel (DB RCT)−43%1.43 · 0.76–2.68death19/9814/103ACTIV-5 BET-C

Late treatment−43%1.43 · 0.76–2.6819/9814/10343% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.27

All studies−43%1.43 · 0.76–2.6819/9814/10343% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.2700.511.52+

Rotate screen for more detailsIncrease width for more details

← Danicopan
reduces riskDanicopan
increases risk →

c19early.org

October 2026

Danicopan COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Beigel (DB RCT)−54%1.54 · 1.09–2.17no recov.96 (n)99 (n)ACTIV-5 BET-C

Late treatment−54%1.54 · 1.09–2.1896 (n)99 (n)54% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.015

All studies−54%1.54 · 1.09–2.1896 (n)99 (n)54% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.01500.511.52+

Rotate screen for more detailsIncrease width for more details

← Danicopan
reduces riskDanicopan
increases risk →

c19early.org

October 2026

Danicopan COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Beigel (DB RCT)−43%1.43 · 0.76–2.68death19/9814/103ACTIV-5 BET-C

Late treatment−43%1.43 · 0.76–2.6819/9814/10343% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.27

All studies−43%1.43 · 0.76–2.6819/9814/10343% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.2700.511.52+

Rotate screen for more detailsIncrease width for more details

← Danicopan
reduces riskDanicopan
increases risk →

c19early.org

October 2026

Danicopan COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Beigel (DB RCT)−43%1.43 · 0.76–2.6819/9814/103ACTIV-5 BET-C

Late treatment−43%1.43 · 0.76–2.6819/9814/10343% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.27

All studies−43%1.43 · 0.76–2.6819/9814/10343% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.2700.511.52+

Rotate screen for more detailsIncrease width for more details

← Danicopan
reduces riskDanicopan
increases risk →

c19early.org

October 2026

Danicopan COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Beigel (DB RCT)−43%1.43 · 0.76–2.68death19/9814/103ACTIV-5 BET-C Beigel (DB RCT)−17%1.17 · 0.61–2.25ventilation16/9114/93ACTIV-5 BET-C Beigel (DB RCT)−54%1.54 · 1.09–2.17no recov.96 (n)99 (n)ACTIV-5 BET-C Beigel (DB RCT)−37%1.37 · 0.99–1.90no improv.96 (n)99 (n)ACTIV-5 BET-C Beigel (DB RCT)−30%1.30 · 0.94–1.79no improv.96 (n)99 (n)ACTIV-5 BET-C Beigel (DB RCT)−19%1.19 · 0.80–1.76hosp. time96 (n)99 (n)ACTIV-5 BET-C

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Danicopan
reduces riskDanicopan
increases risk →